Sullivan LD - Search Results

1

A metastatic and androgen-sensitive human prostate cancer model using intraprostatic inoculation of LNCaP cells in SCID mice.

Sato N, Gleave ME, Bruchovsky N, Rennie PS, Beraldi E, Sullivan LD. Sato N, et al. Among authors: sullivan ld. Cancer Res. 1997 Apr 15;57(8):1584-9. Cancer Res. 1997. PMID: 9108464

2

Butyrate analogue, isobutyramide, inhibits tumor growth and time to androgen-independent progression in the human prostate LNCaP tumor model.

Gleave ME, Sato N, Sadar M, Yago V, Bruchovsky N, Sullivan L. Gleave ME, et al. J Cell Biochem. 1998 Jun 1;69(3):271-81. J Cell Biochem. 1998. PMID: 9581866

3

Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report.

Goldenberg SL, Bruchovsky N, Gleave ME, Sullivan LD, Akakura K. Goldenberg SL, et al. Among authors: sullivan ld. Urology. 1995 May;45(5):839-44; discussion 844-5. doi: 10.1016/s0090-4295(99)80092-2. Urology. 1995. PMID: 7538246 Clinical Trial.

4

Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen.

Akakura K, Bruchovsky N, Goldenberg SL, Rennie PS, Buckley AR, Sullivan LD. Akakura K, et al. Among authors: sullivan ld. Cancer. 1993 May 1;71(9):2782-90. doi: 10.1002/1097-0142(19930501)71:9<2782::aid-cncr2820710916>3.0.co;2-z. Cancer. 1993. PMID: 7682149

5

Teratoma in primary testis tumor reduces complete response rates in the retroperitoneum after primary chemotherapy. The case for primary retroperitoneal lymph node dissection of stage IIb germ cell tumors with teratomatous elements.

Rabbani F, Gleave ME, Coppin CM, Murray N, Sullivan LD. Rabbani F, et al. Among authors: sullivan ld. Cancer. 1996 Aug 1;78(3):480-6. doi: 10.1002/(SICI)1097-0142(19960801)78:3<480::AID-CNCR15>3.0.CO;2-V. Cancer. 1996. PMID: 8697394

6

Optimal duration of neoadjuvant androgen withdrawal therapy before radical prostatectomy in clinically confined prostate cancer.

Gleave ME, Goldenberg SL, Jones EC, Bruchovsky N, Kinahan J, Sullivan LD. Gleave ME, et al. Among authors: sullivan ld. Semin Urol Oncol. 1996 May;14(2 Suppl 2):39-45; discussion 46-7. Semin Urol Oncol. 1996. PMID: 8725890 Review.

7

[Hormone release and intermittent hormonal therapy in the LN CaP model of human prostate cancer].

Gleave M, Santo N, Rennie PS, Goldenberg SL, Bruchovsky N, Sullivan LD. Gleave M, et al. Among authors: sullivan ld. Prog Urol. 1996 Jun;6(3):375-85. Prog Urol. 1996. PMID: 8763692 French.

8

Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model.

Sato N, Gleave ME, Bruchovsky N, Rennie PS, Goldenberg SL, Lange PH, Sullivan LD. Sato N, et al. Among authors: sullivan ld. J Steroid Biochem Mol Biol. 1996 May;58(2):139-46. doi: 10.1016/0960-0760(96)00018-0. J Steroid Biochem Mol Biol. 1996. PMID: 8809195

9

Neoadjuvant androgen withdrawal therapy decreases local recurrence rates following tumor excision in the Shionogi tumor model.

Gleave ME, Sato N, Goldenberg SL, Stothers L, Bruchovsky N, Sullivan LD. Gleave ME, et al. Among authors: sullivan ld. J Urol. 1997 May;157(5):1727-30. J Urol. 1997. PMID: 9112514

10

Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer.

Gleave ME, Goldenberg SL, Jones EC, Bruchovsky N, Sullivan LD. Gleave ME, et al. Among authors: sullivan ld. J Urol. 1996 Jan;155(1):213-9. J Urol. 1996. PMID: 7490838 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

53 results

Search Page

Filters